Temsirolimus Has Activity in Non-mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2010 Sep 15

PMID 20837940

Citations 79

Authors

Sonali M Smith

Koen Van Besien

Theodore Karrison

Janet Dancey

Peter McLaughlin

Anas Younes

Scott Smith

Patrick Stiff

Eric Lester

Sanjiv Modi

L Austin Doyle

Everett E Vokes

Barbara Pro

Affiliations

Soon will be listed here.

Abstract

Purpose: Despite high initial remission rates, most lymphomas relapse and require further therapy. The mammalian target of rapamycin (mTOR) pathway is a validated target in mantle cell lymphoma, but has not been extensively evaluated in other lymphomas.

Patients And Methods: We performed a phase II trial of single-agent temsirolimus 25-mg weekly in patients with relapsed aggressive and indolent lymphomas. The primary objective was overall and complete response rate. Patients were stratified by histology: group A (diffuse large B-cell lymphoma, transformed follicular lymphoma), group B (follicular lymphoma), and group C (chronic lymphocytic leukemia/small lymphocytic lymphoma, and other indolent lymphomas).

Results: Eighty-nine patients were treated, with outcome strongly dependent on histology. Group A had an overall and complete response rate of 28.1% and 12.5%, respectively, and median progression-free survival (PFS) of 2.6 months and median overall survival (OS) of 7.2 months. Group B had overall and complete response rates of 53.8% and 25.6%, respectively, and median PFS of 12.7 months; median OS has not yet been reached. Group C had a partial response rate of 11% with no complete responders. Toxicity was mainly mild and/or reversible myelosuppression and mucositis; however, four patients developed pneumonitis.

Conclusions: Single-agent temsirolimus has significant activity in both diffuse large B-cell lymphoma and follicular lymphoma, although the durability of responses and PFS are longer for patients with follicular lymphoma. This is the first report of substantial activity of temsirolimus in lymphomas other than mantle cell lymphoma, and supports further evaluation of mTOR as a target in these diseases.

Citing Articles

mTOR inhibitors potentially preserve fertility in female patients with haematopoietic malignancies: a narrative review.

Tanaka Y, Amano T, Nakamura A, Deguchi M, Takahashi A, Tsuji S Ann Hematol. 2024; 103(12):4953-4969.

PMID: 39537993 DOI: 10.1007/s00277-024-06090-3.

Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma.

Shi A, Yun F, Shi L, Liu X, Jia Y Ann Med. 2024; 56(1):2329130.

PMID: 38489405 PMC: 10946270. DOI: 10.1080/07853890.2024.2329130.

Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature.

Parigger T, Drothler S, Scherhaufl C, Gassner F, Schubert M, Steiner M Acta Haematol. 2024; 147(5):604-611.

PMID: 38402867 PMC: 11441378. DOI: 10.1159/000537791.

PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities.

Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A Cancers (Basel). 2023; 15(21).

PMID: 37958470 PMC: 10648005. DOI: 10.3390/cancers15215297.

The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects.

Karatrasoglou E, Dimou M, Piperidou A, Lakiotaki E, Korkolopoulou P, Vassilakopoulos T Int J Mol Sci. 2023; 24(18).

PMID: 37762410 PMC: 10531792. DOI: 10.3390/ijms241814110.

References

Frost P, Shi Y, Hoang B, Gera J, Lichtenstein A . Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther. 2009; 8(1):83-93. PMC: 2651087. DOI: 10.1158/1535-7163.MCT-08-0254. View

Boni J, Hug B, Leister C, Sonnichsen D . Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol. 2009; 36 Suppl 3:S18-25. DOI: 10.1053/j.seminoncol.2009.10.009. View

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

Witzig T, Geyer S, Ghobrial I, Inwards D, Fonseca R, Kurtin P . Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005; 23(23):5347-56. DOI: 10.1200/JCO.2005.13.466. View

Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C . Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009; 27(23):3822-9. DOI: 10.1200/JCO.2008.20.7977. View

Yee K, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A . Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006; 12(17):5165-73. DOI: 10.1158/1078-0432.CCR-06-0764. View

Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C . Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol. 2006; 134(5):475-84. DOI: 10.1111/j.1365-2141.2006.06210.x. View

Proud C . The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst). 2004; 3(8-9):927-34. DOI: 10.1016/j.dnarep.2004.03.012. View

Hudes G, Berkenblit A, Feingold J, Atkins M, Rini B, Dutcher J . Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol. 2009; 36 Suppl 3:S26-36. DOI: 10.1053/j.seminoncol.2009.10.013. View

10.

Cheson B, Bennett J, Grever M, Kay N, Keating M, OBrien S . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87(12):4990-7. View

11.

Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D . PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood. 2007; 111(1):285-91. DOI: 10.1182/blood-2007-04-085092. View

12.

Gupta M, Ansell S, Novak A, Kumar S, Kaufmann S, Witzig T . Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009; 114(14):2926-35. PMC: 2756203. DOI: 10.1182/blood-2009-05-220889. View

13.

Sakai A, Thieblemont C, Wellmann A, Jaffe E, Raffeld M . PTEN gene alterations in lymphoid neoplasms. Blood. 1998; 92(9):3410-5. View

14.

Leseux L, Hamdi S, Al Saati T, Capilla F, Recher C, Laurent G . Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006; 108(13):4156-62. DOI: 10.1182/blood-2006-05-026203. View

15.

Ruggero D, Pandolfi P . Does the ribosome translate cancer?. Nat Rev Cancer. 2003; 3(3):179-92. DOI: 10.1038/nrc1015. View

16.

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

17.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

18.

Gera J, Mellinghoff I, Shi Y, Rettig M, Tran C, Hsu J . AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2003; 279(4):2737-46. DOI: 10.1074/jbc.M309999200. View

19.

Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate T . Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukemia. 1998; 12(8):1277-80. DOI: 10.1038/sj.leu.2401099. View

20.

. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs R D. 2004; 5(6):363-7. DOI: 10.2165/00126839-200405060-00011. View